> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Ok’s Prosthetic Joint Infections Study
- URL: https://www.fdaweb.com/fda-oks-prosthetic-joint-infections-study/
- Published: 2024-11-04T12:00:00.000Z
- Updated: 2026-09-14T14:46:02.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5158114

FDA has approved a Phaxiam Therapeutics IND for a Phase 2 study (GLORIA) to evaluate its anti-*Staphylococcus aureus* (*S. aureus*) phages in prosthetic joint infections (PJI) caused by the bacteria. The study plans to include 100 patients with PJI (hip or knee replacement) with open surgical debridement who will be treated with the anti-*S. aureus* phages or placebo, in combination with antibiotics.

PJI is described as a severe complication that affects thousands of patients who have received hip or knee replacements, with over 50,000 new cases reported each year in Western countries. The company says that current standards of care show a failure rate of 50%, with high risks of reinfection (60%), and mortality (25% at five years).